



DOT™ Spectacle Lenses Surpass Two Million Wearers

Milestone Achieved Less Than One Year After Reaching One Million Children, Reflecting Surging Demand for Contrast Management–Based Myopia Control

DALLAS, August 24, 2026—[SightGlass Vision](#) today announced that two million children worldwide have now worn DOT™ spectacle lenses, reaching this milestone less than a year after surpassing the one million mark.^[1]* This demonstrates rapid adoption of the lenses as eye care professionals seek effective ways to slow myopia progression in children. Powered by Diffusion Optics Technology™, DOT lenses are the first lenses that provide myopia control through contrast management.^{[2],[3]}

“Two million children in DOT lenses is a powerful reminder of why we do this work, and a testament to the need for this safe and effective myopia control treatment,” said Andrew Sedgwick, CEO of SightGlass Vision. “We’re proud that so many eye care professionals trust DOT lenses to correct their young patients’ vision today and help reduce future eye health risks,^{[4],[5]} and reaching this milestone only energizes us further to work alongside the clinicians who are pushing the field forward.”

The clinical expertise and personal drive of the eye care professionals who have made DOT lenses a cornerstone of their myopia management practice are key to this achievement.

“In my practice, DOT lenses have been one of the easiest myopia-control options for children to adapt to,” said Teddy Chow at The Chow Eye Institute, one of the earliest adopters of DOT lenses in Canada. “Most kids stop noticing them within days and simply wear them as their everyday glasses. In today’s crowded field of myopia treatments, that counts for a lot. As I tell many parents, it isn’t

about which option edges out another on paper; the best treatment is always the one a child will actually wear, consistently. For the right patients, DOT lenses do both: clear, comfortable vision kids are happy to wear, and the reassurance for parents that their child's myopia is being actively managed."

"Parents are often surprised to learn how quickly myopia can progress in young children. Screen time has accelerated what was already a growing concern across the U.K., and that makes early intervention more important than ever," said Craig McArthur at Peter Ivins Eye Care, one of the first practices prescribing DOT lenses with contrast management in the U.K. "DOT lenses fill the need for an easy and highly effective solution to offer families, and having strong clinical evidence behind that recommendation gives us greater confidence in those conversations with parents."

Underpinning this growth is pivotal new clinical data demonstrating that DOT lenses saved more than 1D of myopia progression on average after two years in Chinese children aged 6 to 10.^{6†} This two-year data from SightGlass Vision's CATHAY study also found that the lenses slowed average myopia progression by 67% (0.78D) and average axial length progression by 62% (0.40 mm) after two years of wear across the full study population of patients in China aged 6 to 13 versus the control group.^{6†}

"The response to DOT lenses in China has been extraordinary," said Yuping Chen, Commercial Director for China at SightGlass Vision. "Few countries feel the weight of childhood myopia as acutely as we do, and it's been deeply rewarding to see so many practitioners make contrast management part of how they care for children, with so many families placing their trust in it as well. This is exactly the kind of progress we hoped for, and the momentum here shows no signs of slowing."

The lenses' performance is rooted in research showing that contrast levels of artificial versus natural environments may lead to very different levels of eye growth.⁷ To mimic more natural contrast, DOT lenses' unique design integrates thousands of elements that softly scatter light before it hits the retina.⁸ SightGlass Vision recently introduced its [Control the Contrast](#) professional education campaign to help more eye care professionals understand and apply this science.

DOT lenses first became available in 2021 and have since made their commercial debut in Canada, China, Israel, Spain, and the U.K., with additional market introductions anticipated in 2026.

Founded in 2016, SightGlass Vision operates as a joint venture of CooperVision, Inc. and Essilor International. For more information, visit SightGlassVision.com.

###

About SightGlass Vision

SightGlass Vision™ develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on landmark discoveries surrounding myopia progression. DOT™ spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina. DOT™ lenses provide myopia control through contrast management and have proven results from Gold-standard clinical trials in North America and China. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

** DOT lenses are not available for sale in all countries, including in the U.S.*

† Prescribed DOT lens wear time was 10 hours per day.

‡ LS mean progression difference of 1.01D between test and control groups.

Diffusion Optics Technology and DOT are trademarks of SightGlass Vision, Inc. © 2026 SightGlass Vision, Inc. All Rights Reserved.

Media Contact

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or carson@mcdougallpr.com

^[1] SGV data on file 2026: 2024-26 sales data and repeat purchase rates; reflects global usage across multiple regions.

^[2] Wolffsohn SJ et al. Visual impact of diffusion optic technology lenses for myopia control. *Ophthalmic Physiol Opt* 2024; 44: 1398–1406.

^[3] SGV data on file, 2023.

^[4] Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): BMJ Open Ophthalmology 2024;9:e001790;

^[5] Bullimore MA, Brennan NA. Myopia Control: Why Each Diopter Matters. Optom Vis Sci 2019;96(6):463–465.

⁶ SGV data on file 2026. Control of myopia using contrast modulation spectacle lenses in a Chinese population (n = 172 (6-10 years: 117), 5 sites in China). Overall patient population aged 6–13 years. The clinical trial was designed to compare DOT lenses with conventional single vision lenses to evaluate their continued safety and efficacy in Chinese children.

⁷ Neitz M et al. Insight from OPN1LW Gene Haplotypes into the Cause and Prevention of Myopia. Genes. 2022;13(6):942

⁸ Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. Br J Ophthalmol 2023;107:1709-1715.1.